AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
06 avr. 2023 16h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
27 mars 2023 18h50 HE
|
AnaptysBio, Inc.
Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction in the risk of disease progression or death...
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
01 mars 2023 16h05 HE
|
AnaptysBio, Inc.
Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic...
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
27 févr. 2023 16h05 HE
|
AnaptysBio, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan...
AnaptysBio Announces Stock Repurchase Plan
13 janv. 2023 09h00 HE
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
05 janv. 2023 16h05 HE
|
AnaptysBio, Inc.
Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to...
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
02 déc. 2022 09h00 HE
|
AnaptysBio, Inc.
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer...
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
21 nov. 2022 13h56 HE
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio to Participate in Upcoming November Investor Conferences
09 nov. 2022 14h10 HE
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
08 nov. 2022 16h05 HE
|
AnaptysBio, Inc.
Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023Anticipate ANB032, our anti-BTLA agonist...